Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 11 of 11 publications.
Skip to main content
Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.
Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687
Arana A, Margulis AV, Varas-Lorenzo C, Bui CL, Gilsenan A, McQuay LJ, Reynolds M, Rebordosa C, Franks B, de Vogel S, Appenteng K, Perez-Gutthann S. Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Arana A, Varas-Lorenzo C, McQuay LJ, Ziemiecki R, Bui CL, Gilsenan AW, Rothman KJ, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Margulis AV, Perez Gutthann S. Do individual antimuscarinic drugs to treat overactive bladder have different cardiovascular risks? A UK CPRD cohort study. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):534-5.
Fortuny J, Kaye JA, Bui CL, Gilsenan AW, Bartsch J, Plana E, McQuay LJ, Calingaert B, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S, Arana A, Margulis AV. Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Assessing the impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Poster presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2007.
Naslund M, Gilsenan AW, Midkiff KD, Wolford E, Bown A, Wang J. The prevalence of luts and prostate enlargement in the primary care setting. Poster presented at the Annual Meeting of the American Urological Association; 2007.
Leone P, Fleming DT, Gilsenan A, Li L, Justus S. Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex Transm Dis. 2004 May 31;31(5):311-6.
Gilsenan A, Pedrazzani S, Bennett L, Li L, Yeager W, Haas JC. Observational prevalence study of HSV-2 (Genital Herpes) in suburban primary-care practices: data collection procedures and sampling methods. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 21, 2003.
Fleming D, Leone P, Gilsenan AW, Li L, Deeter R, Justus S. Seroprevalence of hsv-2 in suburban primary care offices. Poster presented at the ISSTDR Congress; 2003.
Justus S, Williams VS, Li L, Gilsenan AW, Fleeman K, Deeter R. African-American subgroup results from an hsv-2 seroprevalence study in suburban primary care physician offices. Poster presented at the ICAAC; 2003.